Driving long term value from biotech platform deals

Michael Ward
Global Head of LS&H Thought Leadership
Helen Tayton-Martin
Chief Business Officer & Co-Founder
Kendra Rose
VP and Head of New Platforms, Ophthalmology and Hemophilia
Faical Miyara
Head of Global Partnering Oncology

One of the fastest growing investment areas in biotech is around enabling technologies and platforms, such as gene and cell therapies, ADCs, RNA technologies and AI/ML applications. And with good reason, as a single platform deal has the potential to fuel a multitude of life-saving treatments.

In this panel, Mike Ward was joined by industry leaders from big pharma and biotech companies to discuss learnings from their technology partnerships and examine what factors help drive successful deals and long-term portfolio value.

Takeaways from this panel include:

  • What are pharma companies looking for in a technology platform partner? How can biotechs position their platforms to be most attractive to potential suitors?
  • What types of emerging platform providers should pharma keep an eye on? Where is the white space and areas to maximize ROI?
  • What are some of the trends in relationship management, and how can you best set expectations on both sides?